Biocartis to raise €60m in ABB for research and development

Biocartis, the Belgian developer of molecular diagnostics systems, has launched a €60m accelerated capital increase to finance product development, sales and marketing and the expansion of its manufacturing capacities.

  • By Aidan Gregory
  • 28 Nov 2017

JP Morgan, Bank Degroof Petercam and KBC Securities are bookrunners.

Launched at around 3.40pm London time, the block of up to 8.9m new shares is a 20% capital increase.

Genomic Health will subscribe for €4m of shares in the placing. The UK maker of genome-based diagnostic ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Citi 162,719.54 628 8.01%
2 JPMorgan 151,101.13 653 7.44%
3 Bank of America Merrill Lynch 147,779.52 484 7.28%
4 Barclays 124,794.16 438 6.15%
5 Goldman Sachs 108,281.07 343 5.33%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 JPMorgan 25,947.26 30 9.74%
2 Citi 16,842.42 38 6.32%
3 SG Corporate & Investment Banking 15,575.88 46 5.84%
4 Deutsche Bank 14,198.98 44 5.33%
5 Bank of America Merrill Lynch 13,028.84 31 4.89%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Goldman Sachs 6,961.44 31 9.30%
2 JPMorgan 6,815.38 29 9.10%
3 UBS 5,503.59 15 7.35%
4 Citi 5,145.98 30 6.87%
5 Deutsche Bank 4,303.27 25 5.75%